2026 Global: Artificial Intelligence (Ai) In Genomics Market-Competitive Review (2032) report
Description
The 2026 Global: Artificial Intelligence (Ai) In Genomics Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for artificial intelligence (ai) in genomics market by geography and historical trend. The scope of the report extends to sizing of the artificial intelligence (ai) in genomics market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
BenevolentAI, Deep Genomics, Illumina, NVIDIA, Microsoft, SOPHiA GENETICS, DNAnexus, Fabric Genomics, Tempus, and Lifebit are widely recognized as ten major companies active in the AI in genomics market, each combining computational platforms with genomics to accelerate discovery and clinical translation.
BenevolentAI applies machine learning and knowledge-graph approaches to transform biomedical data into therapeutic hypotheses and drug candidates, partnering with pharma to shorten target-to-candidate timelines. Deep Genomics focuses on applying deep learning to predict the impact of genetic variants on molecular processes and to design oligonucleotide therapeutics, using AI to prioritize disease-causing variants and guide therapeutic development. Illumina, historically a leader in sequencing technology, integrates AI across sequencing workflows and collaborates with academic and clinical centers to develop AI-driven genomics solutions for variant interpretation and drug discovery. NVIDIA acts as a foundational enabler by providing GPU-accelerated computing platforms, software libraries, and validated AI toolkits that power large-scale genomic data processing and training of deep learning models used throughout genomics pipelines. Microsoft leverages Azure’s cloud and AI services to host scalable genomics data management, build pipelines for variant calling and interpretation, and support bioinformatics platforms used by research and clinical customers.
SOPHiA GENETICS offers a clinical-grade analytics platform that combines AI and curated knowledgebases to assist diagnostic labs and hospitals in interpreting genomic and multi-omic data for oncology and rare disease applications. DNAnexus provides a secure, compliant cloud-native platform for managing, analyzing, and collaborating on large-scale genomic and multi-omic datasets, enabling teams to deploy AI-powered workflows and integrate third-party AI tools at scale. Fabric Genomics develops AI-driven clinical interpretation software that automates variant classification and accelerates rare disease diagnosis and oncology reporting through curated knowledgebases and machine-learned prioritization. Tempus integrates genomic sequencing with clinical and molecular data, applying machine learning to generate decision-support insights for oncology care and to stratify patients for trials and precision therapies. Lifebit delivers a cloud-native, privacy-preserving genomics platform that combines AI-ready data harmonization, federated analytics, and orchestration to enable collaborative discovery across institutions without centralizing sensitive data.
Collectively these companies span foundational infrastructure (NVIDIA, Microsoft), sequencing and data generation (Illumina), cloud-native data management and compliant platforms (DNAnexus, Lifebit), clinical-grade interpretation and diagnostics (SOPHiA GENETICS, Fabric Genomics, Tempus), and AI-native therapeutic discovery (BenevolentAI, Deep Genomics), reflecting the market’s dual emphasis on scalable compute and clinically actionable AI interpretation in genomics.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for artificial intelligence (ai) in genomics market by geography and historical trend. The scope of the report extends to sizing of the artificial intelligence (ai) in genomics market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
BenevolentAI, Deep Genomics, Illumina, NVIDIA, Microsoft, SOPHiA GENETICS, DNAnexus, Fabric Genomics, Tempus, and Lifebit are widely recognized as ten major companies active in the AI in genomics market, each combining computational platforms with genomics to accelerate discovery and clinical translation.
BenevolentAI applies machine learning and knowledge-graph approaches to transform biomedical data into therapeutic hypotheses and drug candidates, partnering with pharma to shorten target-to-candidate timelines. Deep Genomics focuses on applying deep learning to predict the impact of genetic variants on molecular processes and to design oligonucleotide therapeutics, using AI to prioritize disease-causing variants and guide therapeutic development. Illumina, historically a leader in sequencing technology, integrates AI across sequencing workflows and collaborates with academic and clinical centers to develop AI-driven genomics solutions for variant interpretation and drug discovery. NVIDIA acts as a foundational enabler by providing GPU-accelerated computing platforms, software libraries, and validated AI toolkits that power large-scale genomic data processing and training of deep learning models used throughout genomics pipelines. Microsoft leverages Azure’s cloud and AI services to host scalable genomics data management, build pipelines for variant calling and interpretation, and support bioinformatics platforms used by research and clinical customers.
SOPHiA GENETICS offers a clinical-grade analytics platform that combines AI and curated knowledgebases to assist diagnostic labs and hospitals in interpreting genomic and multi-omic data for oncology and rare disease applications. DNAnexus provides a secure, compliant cloud-native platform for managing, analyzing, and collaborating on large-scale genomic and multi-omic datasets, enabling teams to deploy AI-powered workflows and integrate third-party AI tools at scale. Fabric Genomics develops AI-driven clinical interpretation software that automates variant classification and accelerates rare disease diagnosis and oncology reporting through curated knowledgebases and machine-learned prioritization. Tempus integrates genomic sequencing with clinical and molecular data, applying machine learning to generate decision-support insights for oncology care and to stratify patients for trials and precision therapies. Lifebit delivers a cloud-native, privacy-preserving genomics platform that combines AI-ready data harmonization, federated analytics, and orchestration to enable collaborative discovery across institutions without centralizing sensitive data.
Collectively these companies span foundational infrastructure (NVIDIA, Microsoft), sequencing and data generation (Illumina), cloud-native data management and compliant platforms (DNAnexus, Lifebit), clinical-grade interpretation and diagnostics (SOPHiA GENETICS, Fabric Genomics, Tempus), and AI-native therapeutic discovery (BenevolentAI, Deep Genomics), reflecting the market’s dual emphasis on scalable compute and clinically actionable AI interpretation in genomics.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.